13.92
0.00 (0.00%)
| Previous Close | 13.92 |
| Open | 14.11 |
| Volume | 51,637 |
| Avg. Volume (3M) | 72,860 |
| Market Cap | 301,899,744 |
| Price / Book | 2.00 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -1.28 |
| Total Debt/Equity (MRQ) | 0.48% |
| Current Ratio (MRQ) | 25.86 |
| Operating Cash Flow (TTM) | -27.29 M |
| Levered Free Cash Flow (TTM) | -10.67 M |
| Return on Assets (TTM) | -15.91% |
| Return on Equity (TTM) | -34.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Aardvark Therapeutics, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.22% |
| % Held by Institutions | 49.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Silverarc Capital Management, Llc | 31 Mar 2025 | 119,496 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 187.36%) | Buy |
| Median | 30.00 (115.52%) | |
| Low | 20.00 (RBC Capital, 43.68%) | Buy |
| Average | 30.00 (115.52%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 11.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Jun 2025 | 40.00 (187.36%) | Buy | 13.52 |
| RBC Capital | 15 May 2025 | 20.00 (43.68%) | Buy | 9.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jun 2025 | Announcement | Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference |
| 19 May 2025 | Announcement | Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions |
| 14 May 2025 | Announcement | Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights |
| 07 May 2025 | Announcement | Aardvark Therapeutics to Present at Upcoming Investor Conferences in May |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |